FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2126162079> ?p ?o ?g. }

• W2126162079 endingPage "530" @default.
• W2126162079 startingPage "524" @default.
• W2126162079 abstract "The importance of tumour necrosis factor-alpha (TNF-alpha) in the pathogenesis of pulmonary sarcoidosis has remained uncertain because of the paucity of clinical features associated with excessive levels of this cytokine. Increased levels of soluble TNF receptors (TNF-R), which are known to inhibit TNF-alpha activity, were recently described in the lungs of subjects with sarcoidosis. We hypothesised that TNF-alpha bioactivity may be inhibited in sarcoidosis by the presence of TNF-R. A study was therefore undertaken to investigate for the first time the relationship between soluble receptors and TNF-alpha bioactivity in the lungs of subjects with sarcoidosis.Alveolar macrophages (AMs) from 16 subjects with histologically proven sarcoidosis and 13 healthy controls were cultured in the presence and absence of lipopolysaccharide (LPS). The subjects with sarcoidosis were grouped by radiological assessment into stage I (n = 6) and stage II/III (n = 10). The cell culture supernatants and bronchoalveolar lavage (BAL) fluid were assayed for TNF bioactivity using the WEHI 164 clone 13 assay. Immunoreactive (bound and free) TNF-alpha and free TNF-Rs (p55 and p75) were determined by ELISA.Bioactive TNF-alpha was undetectable in the BAL fluid of all the subjects with sarcoidosis and most of the healthy controls. However, there was significantly more immunoreactive TNF-alpha in the BAL fluid from subjects with sarcoidosis than from the controls (median values 0.304 ng/ml and 0.004 ng/ml, respectively, 95% CI 0. 076 to 0.455, p<0.001). The levels of both p55 and p75 in the BAL fluid were higher in both sarcoidosis groups than in the controls (p<0.0005 and p<0.001, respectively). In LPS stimulated AM supernatants reduced TNF-alpha bioactivity was seen in subjects with stage I sarcoidosis compared with those with stage II/III disease and healthy controls (median 0.333 ng/ml vs 1.362 ng/ml and 2.385 ng/ml, respectively, p<0.01). This contrasted with increased p55 levels in the AM supernatants derived from subjects with stage I sarcoidosis compared with those with stage II/III disease and healthy controls (median 0.449 ng/ml vs 0.058 ng/ml and 0.078 ng/ml, respectively, p<0.01). The levels of p75 were increased in unstimulated AM cultures in subjects with stage II/III disease compared with those with stage I disease and healthy controls (median 0.326 ng/ml vs 0.064 ng/ml and 0.102 ng/ml, p<0.05).These results indicate that TNF-alpha bioactivity may be inhibited by increased soluble TNF-R in the lungs of subjects with sarcoidosis, and this inhibition may be greater in patients with stage I sarcoidosis than in those with stage II/III disease. This may represent a homeostatic mechanism which protects the lung from excessive TNF production characteristic of chronic inflammation." @default.
• W2126162079 created "2016-06-24" @default.
• W2126162079 creator A5030712727 @default.
• W2126162079 creator A5032680051 @default.
• W2126162079 creator A5044231125 @default.
• W2126162079 date "1999-06-01" @default.
• W2126162079 modified "2023-10-01" @default.
• W2126162079 title "Inter-relationship between tumour necrosis factor-alpha (TNF-alpha ) and TNF soluble receptors in pulmonary sarcoidosis" @default.
• W2126162079 cites W1509933819 @default.
• W2126162079 cites W1539312716 @default.
• W2126162079 cites W1607578883 @default.
• W2126162079 cites W1628237737 @default.
• W2126162079 cites W1760557207 @default.
• W2126162079 cites W1904376825 @default.
• W2126162079 cites W1923921388 @default.
• W2126162079 cites W1967956104 @default.
• W2126162079 cites W1971028997 @default.
• W2126162079 cites W1971427229 @default.
• W2126162079 cites W1973793416 @default.
• W2126162079 cites W1982725712 @default.
• W2126162079 cites W1984284310 @default.
• W2126162079 cites W1987812925 @default.
• W2126162079 cites W1992057177 @default.
• W2126162079 cites W2006367658 @default.
• W2126162079 cites W2015090422 @default.
• W2126162079 cites W2043096497 @default.
• W2126162079 cites W2050515690 @default.
• W2126162079 cites W2054526986 @default.
• W2126162079 cites W2055072883 @default.
• W2126162079 cites W2068103783 @default.
• W2126162079 cites W2072011504 @default.
• W2126162079 cites W2088724025 @default.
• W2126162079 cites W2092416284 @default.
• W2126162079 cites W2104449963 @default.
• W2126162079 cites W2116064835 @default.
• W2126162079 cites W2117206496 @default.
• W2126162079 cites W2131550766 @default.
• W2126162079 cites W2151935662 @default.
• W2126162079 cites W2164974807 @default.
• W2126162079 cites W2166159004 @default.
• W2126162079 cites W2409200474 @default.
• W2126162079 cites W29647042 @default.
• W2126162079 cites W30166364 @default.
• W2126162079 cites W45861294 @default.
• W2126162079 doi "https://doi.org/10.1136/thx.54.6.524" @default.
• W2126162079 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1745499" @default.
• W2126162079 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10335007" @default.
• W2126162079 hasPublicationYear "1999" @default.
• W2126162079 type Work @default.
• W2126162079 sameAs 2126162079 @default.
• W2126162079 citedByCount "29" @default.
• W2126162079 countsByYear W21261620792012 @default.
• W2126162079 countsByYear W21261620792019 @default.
• W2126162079 crossrefType "journal-article" @default.
• W2126162079 hasAuthorship W2126162079A5030712727 @default.
• W2126162079 hasAuthorship W2126162079A5032680051 @default.
• W2126162079 hasAuthorship W2126162079A5044231125 @default.
• W2126162079 hasBestOaLocation W21261620791 @default.
• W2126162079 hasConcept C126322002 @default.
• W2126162079 hasConcept C134018914 @default.
• W2126162079 hasConcept C142724271 @default.
• W2126162079 hasConcept C159110408 @default.
• W2126162079 hasConcept C170493617 @default.
• W2126162079 hasConcept C17991360 @default.
• W2126162079 hasConcept C203014093 @default.
• W2126162079 hasConcept C2775944032 @default.
• W2126162079 hasConcept C2777714996 @default.
• W2126162079 hasConcept C2777961210 @default.
• W2126162079 hasConcept C2778690821 @default.
• W2126162079 hasConcept C2780942790 @default.
• W2126162079 hasConcept C2781301800 @default.
• W2126162079 hasConcept C49453240 @default.
• W2126162079 hasConcept C64943373 @default.
• W2126162079 hasConcept C71924100 @default.
• W2126162079 hasConceptScore W2126162079C126322002 @default.
• W2126162079 hasConceptScore W2126162079C134018914 @default.
• W2126162079 hasConceptScore W2126162079C142724271 @default.
• W2126162079 hasConceptScore W2126162079C159110408 @default.
• W2126162079 hasConceptScore W2126162079C170493617 @default.
• W2126162079 hasConceptScore W2126162079C17991360 @default.
• W2126162079 hasConceptScore W2126162079C203014093 @default.
• W2126162079 hasConceptScore W2126162079C2775944032 @default.
• W2126162079 hasConceptScore W2126162079C2777714996 @default.
• W2126162079 hasConceptScore W2126162079C2777961210 @default.
• W2126162079 hasConceptScore W2126162079C2778690821 @default.
• W2126162079 hasConceptScore W2126162079C2780942790 @default.
• W2126162079 hasConceptScore W2126162079C2781301800 @default.
• W2126162079 hasConceptScore W2126162079C49453240 @default.
• W2126162079 hasConceptScore W2126162079C64943373 @default.
• W2126162079 hasConceptScore W2126162079C71924100 @default.
• W2126162079 hasIssue "6" @default.
• W2126162079 hasLocation W21261620791 @default.
• W2126162079 hasLocation W21261620792 @default.
• W2126162079 hasLocation W21261620793 @default.
• W2126162079 hasLocation W21261620794 @default.
• W2126162079 hasOpenAccess W2126162079 @default.
• W2126162079 hasPrimaryLocation W21261620791 @default.
• W2126162079 hasRelatedWork W1990717759 @default.

• next